医学
改良兰金量表
冲程(发动机)
随机对照试验
急性中风
纳入和排除标准
闭塞
临床试验
外科
缺血性中风
内科学
缺血
组织纤溶酶原激活剂
替代医学
病理
工程类
机械工程
作者
Shashvat M. Desai,Diogo C Haussen,Amin Aghaebrahim,Alhamza R Al‐Bayati,Roberta Santos,Raul G Nogueira,Tudor Jovin,Ashutosh P. Jadhav
标识
DOI:10.1136/neurintsurg-2018-013923
摘要
Background and purpose The results of the DAWN trial support the benefit of thrombectomy in patients with anterior circulation large vessel occlusion (LVO) acute stroke presenting within 6–24 hours from time last known well (TLKW). We sought to evaluate the characteristics and outcomes of patients who met DAWN criteria but underwent thrombectomy beyond 24 hours of TLKW. Methods A retrospective review of endovascular thrombectomy databases at three comprehensive stroke centers was performed to identify all patients who received thrombectomy beyond 24 hours of TLKW and otherwise met the DAWN criteria. Baseline characteristics, efficacy, and safety outcomes were compared with patients in the DAWN trial intervention arm. Results Twenty-one patients met the inclusion criteria. Rates of successful reperfusion (mTICI2b–3: 81% vs 84%, P=0.72), 90-day functional independence (modified Rankin Scale score 0–2, 43% vs 48%, P=0.68), and symptomatic intracranial hemorrhage (5% vs 6%, P=0.87) were comparable across the two groups. Conclusion Thrombectomy appears to be safe and feasible in patients with acute ischemic stroke due to LVO meeting all DAWN trial criteria but treated beyond 24 hours of TLKW with outcomes comparable to patients in the DAWN trial intervention arm. Further studies are warranted to validate these findings.
科研通智能强力驱动
Strongly Powered by AbleSci AI